Physician profile
Nancy Tsai
NPI 1184732885
$39,263.98
in general payments reported to CMS, 2019-2025
32 companies · $3,705 in 2025
The $3,705 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $1,008 · 2021: $788 · 2022: $1,879 · 2023: $17K · 2024: $14K · 2025: $3,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Honoraria: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,050 · Travel and Lodging: $3,906 · Consulting Fee: $3,900 · Education: $27.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,834.60 |
| Honoraria | $11,125.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,050.00 |
| Travel and Lodging | $3,905.56 |
| Consulting Fee | $3,900.00 |
| Education | $27.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $14,817.12 | 2022-2023 | Tepezza |
| Amgen INC. | $10,461.78 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $2,888.43 | 2021-2025 | |
| Bausch & Lomb Americas INC. | $1,770.98 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Alcon Vision LLC | $1,081.69 | 2022-2025 | Hydrus Microstent, Rocklatan, Eysuvis |
| Oyster Point Pharma, INC. | $1,063.30 | 2022-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $913.16 | 2024-2025 | Xdemvy |
| Abbvie INC. | $897.42 | 2021-2025 | Lumigan, Alphagan P, Vuity |
| Eyevance Pharmaceuticals LLC | $690.35 | 2020-2023 | Flarex |
| New World Medical,INC. | $496.69 | 2022-2024 | Clearpath, Streamline, Kahook Dual Blade |
| Allergan, INC. | $427.82 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $393.95 | 2022-2025 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $383.47 | 2019-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Lensar, INC. | $357.98 | 2025 | Lensar Laser System |
| Novartis Pharmaceuticals Corporation | $322.78 | 2020-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $321.46 | 2025 | M22 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $278.47 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $240.00 | 2019-2020 | |
| Dompe US, INC. | $220.59 | 2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $208.07 | 2019-2024 | Veracity Surgical, Artevo 800, Callisto Eye |
| Glaukos Corporation | $174.55 | 2022 | |
| Harrow Eye, LLC | $168.76 | 2024-2025 | Vevye |
| Lilly USA, LLC | $125.00 | 2019 | |
| Coopervision INC. | $124.71 | 2020-2024 | Paragon Crt |
| Ivantis, INC | $117.91 | 2021 | |
| Ani Pharmaceuticals, INC. | $117.04 | 2024-2025 | Purified Cortrophin Gel |
| Rayner Intraocular Lenses Limited | $55.29 | 2024-2025 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Thea Pharma INC. | $42.89 | 2023-2025 | Iyuzeh |
| Lumenis, INC | $39.20 | 2021 | |
| Alimera Sciences, INC. | $24.56 | 2024 | Iluvien, Yutiq |
| Shire North American Group INC | $23.72 | 2019 | |
| Ocular Therapeutix, INC. | $14.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.